All results / Stories / Stephanie Henkel

Simulations Plus Upgrades Drug Software

Simulations Plus Inc. on Wednesday announced the release of the latest version of its main software product GastroPlus.

MannKind Joins Hunt for EpiPen Replacement

BIOTECH: Price controversy could open market for year-old research project.

Amid fervor over spike in cost of insulin-based EpiPen, MannKind attracts shareholder attention for its own insulin inhaler.

Medical Center Gives Nonprofits Healthy Boost

GRANT: Kaiser Permanente hands out $250,000 to aid 27 organizations in Valley.

Kaiser Permanente Panorama City Medical Center awarded $250,000 in community grant funding to 27 San Fernando Valley nonprofits last month.

Drug Champs Try for Repeat

BIOTECH: Former Kythera execs unveil next billion-dollar idea.

From chin fat to hair and acne: former Kythera execs form another cosmetic treatment startup.

MannKind Passes $1 Million Research Milestone

PHARMA: Payment comes from partnership to develop inhalable drugs.

Valencia biotech MannKind Corp. received a $1 million milestone payment for completing initial formulation studies.

Software Combo to Serve Hospital Data Demand

TECHNOLOGY: Three-way merger will allow tracking of post-visit patient care.

Agoura Hills health care software developer Casamba Inc. has entered into a three-way merger with two other software providers โ€“ Boston-based HealthWyse and TherapySource of Birmingham, Ala.

Medtronic Glucose Monitor Gets Euro Approval

Medical-device maker Medtronic announced Tuesday that its Guardian Connect mobile glucose monitoring system received European Union approval and is slated for sale in 2017.

Medtronic Advances Insulin Pump Technology

MEDICAL DEVICE: First gadget with hybrid closed loop offers to automate delivery.

A new device has hit the market for people with Type 1 diabetes, allowing for better management of glucose levels with a lot less work.

Around the Valleys

News and notes from the greater San Fernando Valley

Semtech Corp. beat Wall Street estimates on adjusted earnings and revenue in its 2017 fiscal second quarter.

Doctors Counter Allergy Surge With Surgery

MEDICINE: High pollen levels push demand for balloon sinuplasty procedure.

Allergists and doctors concur that this year is one of the worst allergy seasons in Valley history.

FDAโ€™s Approval Gives Drug Maker Healthy Boost

BIOTECH: Stock analysts downplay impact on shares of skin cancer treatment.

Amgen Inc.โ€™s new skin cancer drug fights disease with disease.

Amgen Cancer Drug Receives European OK

Amgen Inc. announced Monday that the European Commission has approved Imlygic, a first of its kind cancer drug, to treat adults with melanoma.

Hospital Faces Reduced Medicare Payments

Antelope Valley Hospital will face reduced Medicare payments based on a health care quality score, according to the Antelope Valley Press.

Cost-Benefit Quest

New data shows Amgenโ€™s Repatha lowers heart attack risk, but another study found high rejection rates by insurers.

Insurers donโ€™t want to pay for Amgenโ€™s pricey cholesterol drug. Now what?

Reports: Rams Start Spring Training at Cal Lutheran

Next Monday, the Los Angeles Rams will begin the teamโ€™s first offseason training program at California Lutheran University in Thousand Oaks.

Medtronic Signs Diabetic Distribution Deal

Medical technology company Medtronic announced on Wednesday that it has entered into an agreement with health care product provider Henry Schein Medical to exclusively distribute certain diabetes products to primary care doctors in the U.S.

Sienna Secures $40 Million Investment

Sienna Biopharmaceuticals Inc. announced Wednesday that it has completed its Series B financing round, which raised $40 million.

Drug Company to Test International Distribution

PHARMACEUTICAL: Amgen reacquires three products from GlaxoSmithKline.

Thousand Oaks biotech giant Amgen Inc. announced last month that it will reacquire the rights to three of its drugs โ€“ Prolia, XGEVA and Vectibix.

Pfizer to Acquire Kythera Parent Allergan

Drug giant Pfizer Inc. said Monday that it is purchasing Allergan Plc for approximately $160 billion, which would create the worldโ€™s largest drug developer.

Second Sight Tests Visual Cortex Implant

Second Sight Medical Products Inc. on Tuesday announced the first successful human implantation of a wireless visual cortical stimulator โ€“ a big step in the ongoing development of its Orion I Visual Cortical Prosthesis.